Abstract
At the COMPA (Coalition of Medication‐Assisted Treatment Providers and Advocates) Symposium last month in Albany, New York, officials from the New York Office of Addiction Services and Supports (OASAS) presented information on the effects of xylazine, increasingly present in the street supply of opioids, especially fentanyl. Pamela Mund, M.D., OASAS associate medical officer, and Sarah Gorry, M.S., an Empire State Fellow with OASAS, shared the following information. Xylazine is
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
